University of Pittsburgh, Hillman Cancer Center

Pittsburgh, Pennsylvania 15260

1 studies enrolling now · 12 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Renal Cell Carcinoma, B-cell Non-Hodgkin Lymphoma, Castrate-Resistant Prostate Cancer, Central Nervous System Lymphoma, Chronic Myelomonocytic Leukemia, Grade 2 Glioma, High Grade B-cell Lymphoma (HGBCL), Lymphoma, Mantle Cell Lymphoma (MCL), Melanoma, Metastatic Clear Cell Renal Cell Carcinoma

Studies at this site

DALY II USA/ MB-CART2019.1 for DLBCL — Recruiting now
First In Human Study of CX-801 in Advanced Solid Tumors — Recruiting now
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies — Running, not enrolling
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma — Completed
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) — Running, not enrolling
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma — Running, not enrolling
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML — Completed
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants — Stopped early
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma — Stopped early
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma — Completed
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor — Completed
Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden — Completed